Slingshot members are tracking this event:

Xenon (XENE) Expands Ion Channel Neurology Pipeline with Addition of XEN496, a “Phase 3 Ready” Potassium Channel Modulator for the Treatment of Epilepsy

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details
Ezogabine, also known as retigabine, is the only anti-epileptic drug previously approved by the FDA with a mechanism of action that potentiates Kv7-mediated potassium current. Ezogabine was originally approved by the FDA in June 2011 as an adjunctive treatment for adults with focal seizures with or without secondary generalization. GlaxoSmithKline (GSK) marketed ezogabine in various jurisdictions – as Potiga® in the U.S.and Trobalt™ in Europe – but withdrew the drug from the market worldwide in June 2017 citing commercial reasons.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 06, 2018
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Ion Channel Activator, Xen496, Potassium Channel Modulator, Epilepsy